HLA-B*13:01and the Dapsone Hypersensitivity S

New England Journal of Medicine
369, 1620-1628
DOI: 10.1056/nejmoa1213096

Citation Report

#	Article	IF	Citations
1	Principles of Anti-Infective Therapy. , 2012, , 1762-1768.		6
3	HLA and the Pharmacogenomics of Drug Hypersensitivity. , 2014, , 437-465.		5
4	HLA and TCR Recognition of Medications in Severe Cutaneous Adverse Reactions. Current Immunology Reviews, 2014, 10, 51-61.	1.2	3
5	Pharmacogenomics of antimicrobial agents. Pharmacogenomics, 2014, 15, 1903-1930.	0.6	21
6	Different Roads, Same Destination. Journal of Investigative Dermatology, 2014, 134, 1154-1155.	0.3	0
7	Digging Up the Human Genome: Current Progress in Deciphering Adverse Drug Reactions. BioMed Research International, 2014, 2014, 1-9.	0.9	7
8	Genetic Basis of Drug-Induced Liver Injury: Present and Future. Seminars in Liver Disease, 2014, 34, 123-133.	1.8	101
9	Case Report of Two Cases of Fever, Rash, and Organ Involvement during the Treatment of Leprosy. PLoS Neglected Tropical Diseases, 2014, 8, e3130.	1.3	1
10	HLA Associations and Clinical Implications in T-Cell Mediated Drug Hypersensitivity Reactions: An Updated Review. Journal of Immunology Research, 2014, 2014, 1-8.	0.9	58
11	Genotyping for Severe Drug Hypersensitivity. Current Allergy and Asthma Reports, 2014, 14, 418.	2.4	35
12	Therapy of chronic urticaria: a simple, modern approach. Annals of Allergy, Asthma and Immunology, 2014, 112, 419-425.	0.5	43
13	Personalized Pharmacogenomics: Predicting Efficacy and Adverse Drug Reactions. Annual Review of Genomics and Human Genetics, 2014, 15, 349-370.	2.5	128
14	Fever, Rash, and Systemic Symptoms: Understanding the Role of Virus and HLA in Severe Cutaneous Drug Allergy. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 21-33.	2.0	74
15	On the relationship between human papilloma virus vaccine and autoimmune diseases. Autoimmunity Reviews, 2014, 13, 736-741.	2.5	70
16	Drug-induced liver injury: what was new in 2013?. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 959-980.	1.5	10
17	Dapsone Hypersensitivity Syndrome-related Lung Injury without Eosinophilia in the Bronchoalveolar Lavage Fluid. Internal Medicine, 2015, 54, 827-831.	0.3	8
18	The characterization of adrenal insufficiency and identification of its risk factors in patients with plasma cell dyscrasias. American Journal of Hematology, 2015, 90, E202-3.	2.0	3
19	Pathogenesis and diagnosis of delayedâ€type drug hypersensitivity reactions, from bedside to bench and back. Clinical and Translational Allergy, 2015, 5, 31.	1.4	60

#	Article	IF	Citations
20	Spray forming and mechanical properties of a new type powder metallurgy superalloy. Chinese Physics B, 2015, 24, 118107.	0.7	3
21	Cutaneous rash and dapsone-induced hypersensitivity syndrome a common manifestation in adult immune thrombocytopenia. Presentation and outcome in 16 cases. American Journal of Hematology, 2015, 90, E201-E202.	2.0	13
22	Addressing DRESS (drug reaction with eosinophilia and systemic symptoms). Adverse Drug Reaction Bulletin, 2015, 295, 1139-1142.	0.6	3
23	Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms. Asia Pacific Allergy, 2015, 5, 59-67.	0.6	23
24	Drug Hypersensitivity: How Drugs Stimulate T Cells via Pharmacological Interaction with Immune Receptors. International Archives of Allergy and Immunology, 2015, 168, 13-24.	0.9	71
25	Drugs Used in Tuberculosis and Leprosy. Side Effects of Drugs Annual, 2015, 37, 349-365.	0.6	3
26	Evolving models of the immunopathogenesis of TÂcellâ€“mediated drug allergy: The role of host, pathogens, and drug response. Journal of Allergy and Clinical Immunology, 2015, 136, 219-234.	1.5	185
27	Clinical Association Between Pharmacogenomics and Adverse Drug Reactions. Drugs, 2015, 75, 589-631.	4.9	57
28	Role of dermatology in pharmacogenomics: drug-induced skin injury. Pharmacogenomics, 2015, 16, 401-412.	0.6	9
29	Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity. Pharmacogenomics, 2015, 16, 1161-1178.	0.6	25
30	Pharmacogenetic testing in idiosyncratic drugâ€induced liver injury: current role in clinical practice. Liver International, 2015, 35, 1801-1808.	1.9	62
31	Dermatology in China. Journal of Investigative Dermatology Symposium Proceedings, 2015, 17, 12-14.	0.8	3
32	T Cellâ€“Mediated Hypersensitivity Reactions to Drugs. Annual Review of Medicine, 2015, 66, 439-454.	5.0	109
33	Antibiotic Allergy, When to Test, Challenge or Desensitise. , 2016, 5, .		1
34	Dapsone â€“ mechanism of action, safety of use and the role in the treatment of bullous pemphigoid according to current recommendations. Przeglad Dermatologiczny, 2016, 2, 176-184.	0.0	1
35	Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation. International Journal of Molecular Sciences, 2016, 17, 1890.	1.8	39
37	Interpreting Geographic Variations in Results of Randomized, Controlled Trials. New England Journal of Medicine, 2016, 375, 2263-2271.	13.9	71
38	Increased risk of strontium ranelate-related SJS/TEN is associated with HLA. Osteoporosis International, 2016, 27, 2577-2583.	1.3	16

#	Article	IF	Citations
39	Pharmacogenomics and adverse drug reactions: Primetime and not ready for primetime tests. Journal of Allergy and Clinical Immunology, 2016, 138, 943-955.	1.5	18
40	Association of <scp>HLA</scp> genotypes with phenobarbital hypersensitivity in children. Epilepsia, 2016, 57, 1610-1616.	2.6	28
41	HLA and Delayed Drug-Induced Hypersensitivity. International Archives of Allergy and Immunology, 2016, 170, 163-179.	0.9	35
42	Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity. Current Opinion in Infectious Diseases, 2016, 29, 561-576.	1.3	15
43	Human leucocyte antigenâ€“adverse drug reaction associations: from a perspective of ethnicity. International Journal of Immunogenetics, 2017, 44, 7-26.	0.8	10
44	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome and the Rheumatologist. Current Rheumatology Reports, 2017, 19, 3.	2.1	21
45	A Review on Dapsone Hypersensitivity Syndrome Among Chinese Patients with an Emphasis on Preventing Adverse Drug Reactions with Genetic Testing. American Journal of Tropical Medicine and Hygiene, 2017, 96, 16-0628.	0.6	26
46	Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir. Clinical Infectious Diseases, 2017, 64, 1198-1203.	2.9	27
47	Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions. European Journal of Clinical Pharmacology, 2017, 73, 855-865.	0.8	58
48	Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 547-563.	2.0	106
49	Dapsoneâ€induced agranulocytosisâ€"possible involvement of lowâ€activity Nâ€acetyltransferase 2. Fundamental and Clinical Pharmacology, 2017, 31, 580-586.	1.0	6
50	Pharmacogenomics of offâ€target adverse drug reactions. British Journal of Clinical Pharmacology, 2017, 83, 1896-1911.	1.1	48
51	Pharmacogenomic Advances in the Prediction and Prevention of Cutaneous Idiosyncratic Drug Reactions. Clinical Pharmacology and Therapeutics, 2017, 102, 86-97.	2.3	32
52	An update on HLA alleles associated with adverse drug reactions. Drug Metabolism and Personalized Therapy, 2017, 32, 73-87.	0.3	29
53	HLA-DRB1*15:01 and HLA-DRB3*02:02 in PLA2R-Related Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 1642-1650.	3.0	60
54	Patient ethnicity and the risk of immune-mediated adverse drug reactions. Pharmacogenomics, 2017, 18, 1375-1378.	0.6	0
55	Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13. Pharmacogenetics and Genomics, 2017, 27, 429-437.	0.7	87
56	Severe Delayed Drug Reactions. Immunology and Allergy Clinics of North America, 2017, 37, 785-815.	0.7	27

#	Article	IF	Citations
57	Dapsone and Nitroso Dapsone Activation of NaÄ±Ì˜ve T-Cells from Healthy Donors. Chemical Research in Toxicology, 2017, 30, 2174-2186.	1.7	18
58	The 3 Cs of Antibiotic Allergyâ€"Classification, Cross-Reactivity, and Collaboration. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1532-1542.	2.0	60
59	A docking model of dapsone bound to HLA-B*13:01 explains the risk of dapsone hypersensitivity syndrome. Journal of Dermatological Science, 2017, 88, 320-329.	1.0	29
60	Immunomodulatory treatments for persistent and chronic immune thrombocytopenic purpura. Medicine (United States), 2017, 96, e7534.	0.4	9
62	The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions. Immunogenetics, 2017, 69, 617-630.	1.2	63
64	Docking simulations between drugs and HLA molecules associated with idiosyncratic drug toxicity. Drug Metabolism and Pharmacokinetics, 2017, 32, 31-39.	1.1	14
66	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune System. International Journal of Molecular Sciences, 2017, 18, 1243.	1.8	170
67	HLA Association with Drug-Induced Adverse Reactions. Journal of Immunology Research, 2017, 2017, 1-10.	0.9	111
68	Dapsoneâ€induced drug reaction with eosinophilia and systemic symptoms associated with HLAâ€B*13:01. Internal Medicine Journal, 2018, 48, 363-364.	0.5	10
69	Implications of HLA-allele associations for the study of type IV drug hypersensitivity reactions. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 261-274.	1.5	2
70	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 38-69.	2.0	134
71	Amino Acid Variants of HLA-DRB1 Confer Susceptibility to Dapsone Hypersensitivity Syndrome in Addition to HLA-B*13:01. Journal of Investigative Dermatology, 2018, 138, 1101-1106.	0.3	9
72	Missense Variants in HIF1A and LACC1 Contribute to Leprosy Risk in Han Chinese. American Journal of Human Genetics, 2018, 102, 794-805.	2.6	42
73	The Function of HLA-B*13:01 Involved in the Pathomechanism of Dapsone-Induced Severe Cutaneous Adverse Reactions. Journal of Investigative Dermatology, 2018, 138, 1546-1554.	0.3	54
74	Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management. Current Allergy and Asthma Reports, 2018, 18, 26.	2.4	38
75	Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention. Molecular Diagnosis and Therapy, 2018, 22, 297-314.	1.6	15
76	Association Between HLA-B*1301 and Dapsone-Induced Cutaneous Adverse Drug Reactions. JAMA Dermatology, 2018, 154, 441.	2.0	44
77	Pharmacogenomics of Drug Allergy. , 2018, , 39-51.		0

#	Article	IF	Citations
78	HLAs: Key regulators of Tâ€cellâ€mediated drug hypersensitivity. Hla, 2018, 91, 3-16.	0.4	72
79	A Young Woman With Sudden Urinary Retention and Sensory Deficits. Arthritis Care and Research, 2018, 70, 635-642.	1.5	3
80	Major Histocompatibility Complex and Psoriasis. Journal of Investigative Dermatology Symposium Proceedings, 2018, 19, S79-S80.	0.8	3
81	Human Leukocyte Antigen Associations in Drug Hypersensitivity Reactions. Clinics in Laboratory Medicine, 2018, 38, 669-677.	0.7	14
82	Genetic Basis of Delayed Hypersensitivity Reactions to Drugs in Jewish and Arab Populations. Pharmaceutical Research, 2018, 35, 211.	1.7	3
83	Drug reaction with eosinophilia and systemic symptoms (DRESS) and multiple organ dysfunction syndrome (MODS): one more reason for a new effective treatment against leishmaniasis. International Journal of Dermatology, 2018, 57, 1304-1313.	0.5	5
84	Pharmacogenomics in Papua New Guineans. Pharmacogenetics and Genomics, 2018, 28, 153-164.	0.7	6
85	Recent Advances in Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms. Journal of Immunology Research, 2018, 2018, 1-10.	0.9	44
86	An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity. Journal of Immunology Research, 2018, 2018, 1-22.	0.9	111
87	Clinical, Viral and Genetic Characteristics of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in Shanghai, China. Acta Dermato-Venereologica, 2018, 98, 401-405.	0.6	24
88	HLA Pharmacogenetic Markers of Drug Hypersensitivity in a Thai Population. Frontiers in Genetics, 2018, 9, 277.	1.1	24
89	Genetic and nongenetic factors that may predispose individuals to allergic drug reactions. Current Opinion in Allergy and Clinical Immunology, 2018, 18, 325-332.	1.1	11
90	Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions. Annual Review of Pharmacology and Toxicology, 2019, 59, 463-486.	4.2	42
91	Cross-ethnicity tagging SNPs for HLA alleles associated with adverse drug reaction. Pharmacogenomics Journal, 2019, 19, 230-239.	0.9	9
92	Identification of drug-specific public TCR driving severe cutaneous adverse reactions. Nature Communications, 2019, 10, 3569.	5.8	83
93	Antibiotic Hypersensitivity Mechanisms. Pharmacy (Basel, Switzerland), 2019, 7, 122.	0.6	22
94	Cephalosporin Allergy: Current Understanding and Future Challenges. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2105-2114.	2.0	69
95	Immunomodulatory Second-Line Therapies for Immune Thrombocytopenia. Hamostaseologie, 2019, 39, 266-271.	0.9	4

#	Article	IF	Citations
96	Human leukocyte antigen-associated severe cutaneous adverse drug reactions: from bedside to bench and beyond. Asia Pacific Allergy, 2019, 9, e20.	0.6	6
97	Late onset dapsone hypersensitivity syndrome. Medicina ClÃnica (English Edition), 2019, 153, e23-e24.	0.1	0
98	Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. , 2019, 197, 122-152.		83
99	Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS): How Far Have We Come?. American Journal of Clinical Dermatology, 2019, 20, 217-236.	3.3	48
100	HLA-B*13:01 as a Risk Allele for Antiepileptic Drugs-Induced Cutaneous Adverse Reactions: Higher Risk for Cross-Reactivity?. Frontiers in Neurology, 2019, 10, 614.	1.1	3
101	Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances. Drug Safety, 2019, 42, 973-992.	1.4	66
102	Evaluation of ProspectiveHLA-B*13:01Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy. JAMA Dermatology, 2019, 155, 666.	2.0	52
103	Dapsoneâ€•and nitroso dapsoneâ€šspecific activation of T cells from hypersensitive patients expressing the risk allele HLAâ€B*13:01. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1533-1548.	2.7	37
104	Immune pathomechanism and classification of drug hypersensitivity. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1457-1471.	2.7	131
105	Increased Type 2 Innate Lymphoid Cells inÂPatients with Drug Reaction with EosinophiliaÂand Systemic Symptoms Syndrome. Journal of Investigative Dermatology, 2019, 139, 1722-1731.	0.3	19
106	Metabolic, pharmacokinetic, and toxicological issues surrounding dapsone. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 367-379.	1.5	26
107	Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer. International Journal of Molecular Sciences, 2019, 20, 890.	1.8	34
108	Understanding the Use of Antimicrobial Agents. , 2019, , 154-178.		0
109	Liver injury, rash, and encephalopathy in a 23-year-old Asian man prescribed dapsone. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1071-1072.	2.0	2
110	Controversies in drug allergy: Testing for delayed reactions. Journal of Allergy and Clinical Immunology, 2019, 143, 66-73.	1.5	144
111	Controversies in drug allergy: InÂvitro testing. Journal of Allergy and Clinical Immunology, 2019, 143, 56-65.	1.5	94
112	Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions. , 2019, , .		6
113	Conference report: pharmacogenomics in special populations at WCP2018. British Journal of Clinical Pharmacology, 2019, 85, 467-475.	1.1	3

#	Article	IF	Citations
114	SÃndrome de hipersensibilidad a la dapsona de aparici Ã³n tardÃa. Medicina ClÃnica, 2019, 153, e23-e24.	0.3	2
115	Pharmacogenomics and Cutaneous Adverse Drug Reactions. , 2019, , 39-53.		0
116	The skin as a metabolic and immune-competent organ: Implications for drug-induced skin rash. Journal of Immunotoxicology, 2019, 16, 1-12.	0.9	20
117	Drugâ€induced liver injury with skin reactions: Drugs and host risk factors, clinical phenotypes and prognosis. Liver International, 2019, 39, 802-811.	1.9	23
118	The human leukocyte antigen system in human disease and transplantation medicine. , 2020, , 309-325.		0
119	Meeting Report of the 4th Annual Meeting of the Chinese Society for Investigative Dermatology: Reflections on the Rise of Cutaneous Biology Research in China. Journal of Investigative Dermatology, 2020, 140, 729-732.e4.	0.3	1
120	Immune dysregulation increases the incidence of delayedâ€type drug hypersensitivity reactions. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 781-797.	2.7	21
121	Genetic variants associated with T cellâ€“mediated cutaneous adverse drug reactions: A PRISMAâ€compliant systematic reviewâ€”An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1069-1098.	2.7	16
122	Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, S16-S116.	2.0	107
123	Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go?. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2878-2895.e6.	2.0	27
124	Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions. Frontiers in Pharmacology, 2020, 11, 969.	1.6	38
125	The HLA-B*13:01 and the dapsone hypersensitivity syndrome in Korean and Asian populations: genotype- and meta-analyses. Expert Opinion on Drug Safety, 2020, 19, 1349-1356.	1.0	20
126	Detection of HLA-B 13:01 gene among Dapsone hypersensitivity patients of leprosy in Papua Ethnics group using sequence based typing and qPCR rapid detection. AIP Conference Proceedings, 2020, , .	0.3	2
127	Increased risk of occupational trichloroethylene hypersensitivity syndrome at exposure levels higher than 15Âmg/L of urinary trichloroacetic acid, regardless of whether the patients had the HLA-B*13:01 allele. Environmental Research, 2020, 191, 109972.	3.7	5
128	4,4â€²-Diaminodiphenyl Sulfone (DDS) as an Inflammasome Competitor. International Journal of Molecular Sciences, 2020, 21, 5953.	1.8	18
129	HLA-DRB1*15. Investigative Radiology, 2020, 55, 304-309.	3.5	11
130	Genetic Association of Coâ€Trimoxazoleâ€Induced Severe Cutaneous Adverse Reactions Is Phenotypeâ€Specific: HLA Class I Genotypes and Haplotypes. Clinical Pharmacology and Therapeutics, 2020, 108, 1078-1089.	2.3	34
131	An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 723-734.	1.5	12

#	Article	IF	Citations
132	A case of dapsone hypersensitivity syndrome in an Indian leprosy patient: Retrospective screening reveals the genetic connection with <scp>HLAâ€B</scp> *13:01. Dermatologic Therapy, 2020, 33, e13825.	0.8	3
133	Stevens-Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategies. Expert Review of Clinical Immunology, 2020, 16, 373-387.	1.3	20
134	Genetic Diversity of HLA Class I and Class II Alleles in Thai Populations: Contribution to Genotype-Guided Therapeutics. Frontiers in Pharmacology, 2020, 11, 78.	1.6	38
135	SJS/TEN 2019: From science to translation. Journal of Dermatological Science, 2020, 98, 2-12.	1.0	41
136	Association of HLA-A*11:01 with Sulfonamide-Related Severe Cutaneous Adverse Reactions in Japanese Patients. Journal of Investigative Dermatology, 2020, 140, 1659-1662.e6.	0.3	18
138	Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians. Journal of Allergy and Clinical Immunology, 2021, 147, 1402-1412.	1.5	46
139	Drugâ€specific Tâ€cell responses in patients with liver injury following treatment with the BACE inhibitor atabecestat. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1825-1835.	2.7	12
140	An Updated Review of the Diagnostic Methods in Delayed Drug Hypersensitivity. Frontiers in Pharmacology, 2020, 11, 573573.	1.6	32
141	Review on Databases and Bioinformatic Approaches on Pharmacogenomics of Adverse Drug Reactions. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 61-75.	0.4	7
142	The Roles of Immunoregulatory Networks in Severe Drug Hypersensitivity. Frontiers in Immunology, 2021, 12, 597761.	2.2	15
143	Implementation of Pharmacogenomic Information on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Frontiers in Medicine, 2021, 8, 644154.	1.2	2
144	Characterization of T-Cell Responses to SMX and SMX-NO in Co-Trimoxazole Hypersensitivity Patients Expressing HLA-B*13:01. Frontiers in Immunology, 2021, 12, 658593.	2.2	14
145	Genomic Risk Factors Driving Immune-Mediated Delayed Drug Hypersensitivity Reactions. Frontiers in Genetics, 2021, 12, 641905.	1.1	11
146	HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients. Frontiers in Immunology, 2021, 12, 661135.	2.2	29
147	Specific Treatment Exists for SARS-CoV-2 ARDS. Vaccines, 2021, 9, 635.	2.1	11
148	The important role of nonâ€covalent drugâ€protein interactions in drug hypersensitivity reactions. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 404-415.	2.7	24
149	Evaluation of HLA class I and HLA class II allele profile and its relationship with clinical features in patients with alopecia areata: a caseâ€“control study. Journal of Dermatological Treatment, 2022, 33, 2175-2181.	1.1	5
150	Genetics of Severe Cutaneous Adverse Reactions. Frontiers in Medicine, 2021, 8, 652091.	1.2	11

#	Article	IF	Citations
151	GenotypingHLAalleles to predict the development of Severe cutaneous adverse drug reactions (SCARs): state-of-the-art. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1049-1064.	1.5	16
152	Review of culprit drugs associated with patients admitted to the burn unit with the diagnosis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Syndrome. Burns, 2022, 48, 1561-1573.	1.1	6
153	Association of human leukocyte antigenâ€B*13:01 with dapsoneâ€induced liver injury. British Journal of Clinical Pharmacology, 2022, 88, 1369-1372.	1.1	3
154	Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus. Journal of Autoimmunity, 2021, 123, 102707.	3.0	27
155	Clinical Application of Pharmacogenetic Markers in the Treatment of Dermatologic Pathologies. Pharmaceuticals, 2021, 14, 905.	1.7	6
156	HLA Alleleâ€“Restricted Immune-Mediated Adverse Drug Reactions: Framework for Genetic Prediction. Annual Review of Pharmacology and Toxicology, 2022, 62, .	4.2	8
157	HLA Class-IIâ€’Restricted CD8+ T Cells Contribute to the Promiscuous Immune Response in Dapsone-Hypersensitive Patients. Journal of Investigative Dermatology, 2021, 141, 2412-2425.e2.	0.3	12
158	Intraepidermal neutrophilic dermatosis-type immunoglobulin A pemphigus. Dermatologica Sinica, 2021, 39, 47.	0.2	1
159	Skin Diseases Caused by Factors from the Environment. , 2017, , 145-198.		3
160	Diagnosing and managing patients with drug hypersensitivity. Expert Review of Clinical Immunology, 2018, 14, 29-41.	1.3	3
161	Dapsone hypersensitivity syndrome not related to G6PD deficiency. BMJ Case Reports, 2015, 2015, bcr2015212742.	0.2	5
162	Randomized, controlled trial of TNF-Î± antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation, 2018, 128, 985-996.	3.9	185
163	Severe cutaneous adverse reactions: impact of immunology, genetics, and pharnacology. Seminars in Cutaneous Medicine and Surgery, 2014, 33, 17-27.	1.6	12
164	Validation study of HLA-B*13:01 as a biomarker of dapsone hypersensitivity syndrome in leprosy patients in Indonesia. PLoS Neglected Tropical Diseases, 2020, 14, e0008746.	1.3	17
165	Early Biomarkers for Severe Drug Hypersensitivity Reactions. Current Pharmaceutical Design, 2019, 25, 3829-3839.	0.9	8
166	Drug-Induced liver Injury Associated with Severe Cutaneous Hypersensitivity Reactions: A Complex Entity in Need of a Multidisciplinary Approach. Current Pharmaceutical Design, 2019, 25, 3855-3871.	0.9	13
167	Genetic markers of severe cutaneous adverse reactions. Korean Journal of Internal Medicine, 2018, 33, 867-875.	0.7	25
168	Case Report: A Case of Type 1 Leprosy Reaction and Dapsone Hypersensitivity Syndrome Complicating the Clinical Course of Multibacillary Leprosy. American Journal of Tropical Medicine and Hygiene, 2019, 100, 1145-1148.	0.6	6

#	Article	IF	Citations
169	Small Molecule/HLA Complexes Alter the Cellular Proteomic Content. , 0, , .		1
170	Pharmacology: Better safe than dapsone hypersensitivity. Nature China, 0, , .	0.0	0
171	Immunology of Cutaneous Drug Eruptions. , 2015, , 3-12.		0
172	Principles of Anti-infective Therapy. , 2015, , 224-234.e3.		2
173	Adverse Medication Reactions. , 2017, , 439-467.		1
174	Nasopharyngeal Carcinoma (NPC) Related Human Leukocyte Antigen (HLA) Haplotype Sharing among Southern East Asian Population. Global Medical & Health Communication, 2017, 5, 1.	0.1	0
175	Pharmacogenomics: A New Approach for Preventing Severe Cutaneous Adverse Drug Reactions. , 2018, , 373-409.		2
178	An Update on the Immunological, Metabolic and Genetic Mechanisms in Drug Hypersensitivity Reactions. Current Pharmaceutical Design, 2019, 25, 3813-3828.	0.9	2
179	The adverse drug effects of dapsone therapy in leprosy: a systematic review. Leprosy Review, 2020, 91, 232-243.	0.1	5
180	Linear immunoglobulin A bullous dermatosis with severe ocular sequela. Dermatologica Sinica, 2020, 38, 48.	0.2	0
182	Successful Treatment of IgA Vasculitis With Prolonged Cutaneous Manifestation With Colchicine in a 10-Year-Old Boy. Modern Rheumatology Case Reports, 2021, , .	0.3	2
183	Fatal dapsone hypersensitivity syndrome with hypothyroidism and steroid-induced diabetes mellitus. Indian Journal of Pharmacology, 2017, 49, 396-398.	0.4	3
184	Dapsone-induced DRESS after infliximab-induced vasculitis: a case of cerebral infarction in the context of multiple drug reactions. BMJ Case Reports, 2020, 13, .	0.2	1
185	Prevention and Treatment of Leprosy - China, 2009-2019. China CDC Weekly, 2020, 2, 53-56.	1.0	0
186	Immunopharmaco-genomics: future of clinical medicine. , 2022, , 347-384.		0
187	Updates and Insights in the Diagnosis and Management of DRESS Syndrome. Current Dermatology Reports, 2021, 10, 192-204.	1.1	27
188	Critical Review of Gaps in the Diagnosis and Management of Drug-Induced Liver Injury Associated with Severe Cutaneous Adverse Reactions. Journal of Clinical Medicine, 2021, 10, 5317.	1.0	3
189	Dapsone for the treatment of acne vulgaris: do the risks outweigh the benefits?. Cutaneous and Ocular Toxicology, 2022, 41, 60-66.	0.5	4

#	Article	IF	Citations
190	Annular drug eruptions. Clinics in Dermatology, 2021, , .	0.8	2
191	Immunogenetics in the diagnosis of clinical disorders. , 2022, , 35-56.		0
192	Functional and Structural Characteristics of HLA-B*13:01-Mediated Specific T Cells Reaction in Dapsone-Induced Drug Hypersensitivity. SSRN Electronic Journal, 0, , .	0.4	0
193	The Immunogenetics of Cutaneous Drug Reactions. Advances in Experimental Medicine and Biology, 2022, 1367, 411-431.	0.8	1
194	Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1155-1167.e5.	2.0	52
195	Risk Assessment in Drug Hypersensitivity: Detecting Small Molecules Which Outsmart the Immune System. Frontiers in Allergy, 2022, 3, 827893.	1.2	6
196	Sustained Actions in Combating Neglected Tropical Diseases during the COVID-19 Pandemic: Lessons Learned From the Leprosy Program in the Hyper-Endemic Area in Papua Province, Indonesia. Frontiers in Tropical Diseases, 2022, 2, .	0.5	0
197	Advances in the Pathomechanisms of Delayed Drug Hypersensitivity. Immunology and Allergy Clinics of North America, 2022, 42, 357-373.	0.7	5
198	Pharmacogenomics of Drug Hypersensitivity. Immunology and Allergy Clinics of North America, 2022, 42, 335-355.	0.7	6
199	Evolution of HLA-B Pharmacogenomics and the Importance of PGx Data Integration in Health Care System: A 10 Years Retrospective Study in Thailand. Frontiers in Pharmacology, 2022, 13, 866903.	1.6	3
200	The anti-inflammatory effect of dapsone on ovalbumin-induced allergic rhinitis in balb/c mice. Life Sciences, 2022, 297, 120449.	2.0	3
201	Stevensâ€“Johnson Syndrome and Toxic Epidermal Necrolysis in the Era of Systems Medicine. Methods in Molecular Biology, 2022, 2486, 37-54.	0.4	5
202	Drug-Induced Severe Cutaneous Adverse Reactions: Insights Into Clinical Presentation, Immunopathogenesis, Diagnostic Methods, Treatment, and Pharmacogenomics. Frontiers in Pharmacology, 2022, 13, 832048.	1.6	17
206	Dapsone-induced DRESS after infliximab-induced vasculitis: a case of cerebral infarction in the context of multiple drug reactions. BMJ Case Reports, 2020, 13, e237560.	0.2	2
207	Progress in study on the association between HLA genetic variation and adverse drug reactions. Journal of Central South University (Medical Sciences), 2021, 46, 404-413.	0.1	0
209	Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS)/Drug-Induced Hypersensitivity Syndrome (DiHS)â€”Readdressing the DReSS. Biomedicines, 2022, 10, 999.	1.4	16
210	An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice. Frontiers in Pharmacology, 2022, 13, 886377.	1.6	14
211	Implementation of genetic screening test to reduce the incidence of dapsone hypersensitivity syndrome among patients with leprosy in Papua, Indonesia: a study protocol. BMJ Open, 2022, 12, e057173.	0.8	1

#	Article	IF	Citations
213	Cutaneous adverse drug reactions among people living with human immunodeficiency virus in a tertiary care hospital in Johor, Malaysia. International Journal of STD and AIDS, 0, , 095646242211037.	0.5	1
214	Advances in the Diagnosis of Leprosy. Frontiers in Tropical Diseases, 0, 3, .	0.5	3
215	Genetic markers of drug hypersensitivity in pediatrics: current state and promise. Expert Review of Clinical Pharmacology, 2022, 15, 715-728.	1.3	2
216	Distribution of HLA-B Alleles and Haplotypes in Qatari: Recommendation for Establishing Pharmacogenomic Markers Screening for Drug Hypersensitivity. Frontiers in Pharmacology, 0, 13, .	1.6	1
217	Functional and structural characteristics of HLA-B*13:01-mediated specific T cells reaction in dapsone-induced drug hypersensitivity. Journal of Biomedical Science, 2022, 29, .	2.6	9
218	Human Leukocyte Antigen (HLA) Testing in Pharmacogenomics. Methods in Molecular Biology, 2022, , 21-45.	0.4	3
219	An update on the management of refractory cutaneous lupus erythematosus. Frontiers in Medicine, 0, 9, .	1.2	5
220	Drug allergy: AÂ2022 practice parameter update. Journal of Allergy and Clinical Immunology, 2022, 150, 1333-1393.	1.5	131
221	Pathology of drug hypersensitivity reactions and mechanisms of immune tolerance. Clinical and Experimental Allergy, 2022, 52, 1379-1390.	1.4	2
222	Basic genetics and epigenetics for the immunologist and allergist. , 2022, , 119-143.		0
223	Pharmacogenetics of Cutaneous Adverse Drug Reactions. Updates in Clinical Dermatology, 2022, , 3-34.	0.1	0
224	Mechanisms of Drug Hypersensitivity. Updates in Clinical Dermatology, 2022, , 35-52.	0.1	0
225	COVID-19 Molecular Pathophysiology: Acetylation of Repurposing Drugs. International Journal of Molecular Sciences, 2022, 23, 13260.	1.8	8
226	Tools to improve the diagnosis and management of T-cell mediated adverse drug reactions. Frontiers in Medicine, 0, 9, .	1.2	4
227	TAP2 Drives HLA-Bâˆ—13:01â€'Linked Dapsone Hypersensitivity Syndrome Tolerance and Reactivity. Journal of Investigative Dermatology, 2023, 143, 722-730.e1.	0.3	4
228	Associations of HLA-A and HLA-B with vancomycin-induced drug reaction with eosinophilia and systemic symptoms in the Han-Chinese population. Frontiers in Pharmacology, 0, 13, .	1.6	4
229	Delayed Drug Hypersensitivity Reactions: Molecular Recognition, Genetic Susceptibility, and Immune Mediators. Biomedicines, 2023, 11, 177.	1.4	2
230	Pharmacogenomics: current status and future perspectives. Nature Reviews Genetics, 2023, 24, 350-362.	7.7	46

#	Article	IF	Citations
231	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Focus on the Pathophysiological and Diagnostic Role of Viruses. Microorganisms, 2023, 11, 346.	1.6	9
232	Dapsone hypersensitivity syndrome. Chinese Medical Journal, 0, Publish Ahead of Print, .	0.9	1
233	Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions. Journal of Allergy and Clinical Immunology, 2023, 151, 289-300.e4.	1.5	13
234	Relevance of Pharmacogenomics to the Safe Use of Antimicrobials. Antibiotics, 2023, 12, 425.	1.5	2
235	Detection of Hepatic Drug Metabolite-Specific T-Cell Responses Using a Human Hepatocyte, Immune Cell Coculture System. Chemical Research in Toxicology, 2023, 36, 390-401.	1.7	4
236	Activation of Human CD8+ T Cells with Nitroso Dapsoneâ€“Modified HLA-B*13:01â€“Binding Peptides. Journal of Immunology, 2023, 210, 1031-1042.	0.4	2
238	Treatment of Leprosy. , 2019, , .		3